ChallengeSarcoma.com is a responsive website designed to educate healthcare professionals and the community at-large about the diagnosis, treatment, and probable outcomes related to advanced soft tissue sarcoma. Soft tissue sarcomas are a type of cancer that originate in the soft tissues that connect, support, and surround other body structures, such as muscle, fat, blood vessels, nerves, tendons, and the lining of joints. Soft tissue sarcomas are often asymptomatic in the early stages and not diagnosed until they have reached the advanced disease, when treatment is limited and long-term survival unlikely. ChallengeSarcoma.com focuses on reorienting physicians and patients toward end points for evaluating treatment other than overall survival that may give them hope, not for a longer life, but more realistically, for a higher quality of life based on these alternative measures of treatment success.

ChallengeSarcoma.com employs a mobile-first approach to communicate its strategic imperatives. The site provides a sequence of information that builds the educational experience from foundation to conclusion in a seamless, logical progression. Each of its single scrolling pages focuses on a specific chapter of the overall unbranded message and features bite-sized, stacked information that makes the content easy to digest. The site employs a number of engagement techniques designed to get users to interact with the content such as delay-to-build infographics and animated visuals that draw the eye to specific content upon scrolling. To underscore the cohesive nature of these elements, parallax scrolling adds to the visual fluidity of the story. It is important to note this was this pharmaceutical company’s first responsive parallax website.

ChallengeSarcoma.com was launched in the first quarter of 2015. Tracking measurements show high traffic volume and extended customer engagement among the primary target audience, oncologists and allied healthcare professional. Post-launch research showed a shift starting among healthcare professionals in their thinking about the criteria for measuring treatment success in patients with advanced soft tissue sarcoma.